www.cnbc.com Open in urlscan Pro
104.92.103.163  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip Navigation
BREAKING
Stocks fall on Friday led by Amazon as the Nasdaq heads for worst month since
March 2020

Moderna asks FDA to authorize Covid vaccine for kids under 6 years old
 * watchliveSquawk on the Street

Markets
 * Pre-Markets
 * U.S. Markets
 * Europe Markets
 * China Markets
 * Asia Markets
 * World Markets
 * Currencies
 * Cryptocurrency
 * Futures & Commodities
 * Bonds
 * Funds & ETFs

Business
 * Economy
 * Finance
 * Health & Science
 * Media
 * Real Estate
 * Energy
 * Climate
 * Transportation
 * Industrials
 * Retail
 * Wealth
 * Life
 * Small Business

Investing
 * Invest In You
 * Personal Finance
 * Fintech
 * Financial Advisors
 * Options Action
 * ETF Street
 * Buffett Archive
 * Earnings
 * Trader Talk

Tech
 * Cybersecurity
 * Enterprise
 * Internet
 * Media
 * Mobile
 * Social Media
 * CNBC Disruptor 50
 * Tech Guide

Politics
 * White House
 * Policy
 * Defense
 * Congress
 * Equity and Opportunity
 * Europe Politics
 * China Politics
 * Asia Politics
 * World Politics

CNBC TV
 * Live Audio
 * Latest Video
 * Top Video
 * CEO Interviews
 * Europe TV
 * Asia TV
 * CNBC Podcasts
 * Digital Originals

Watchlist
Investing Club
 * Newsletter
 * Morning Meeting
 * Trade Alerts
 * Trust Portfolio

PRO
 * Pro News
 * Pro Live
 * Subscribe
 * Sign In



Menu

 * Make It

 * USA
 * INTL

Search quotes, news & videos
Watchlist
SIGN IN
Moderna asks FDA to authorize Covid vaccine for kids under 6 years old
 * watchliveSquawk on the Street

Markets
Business
Investing
Tech
Politics
CNBC TV
Watchlist
Investing Club
PRO


Menu


Health and Science


MODERNA ASKS FDA TO AUTHORIZE COVID VACCINE FOR KIDS UNDER 6 YEARS OLD

Published Thu, Apr 28 20227:07 AM EDTUpdated Thu, Apr 28 20227:11 AM EDT
Spencer Kimball@spencekimball
WATCH LIVE
ShareShare Article via FacebookShare Article via TwitterShare Article via
LinkedInShare Article via Email
Key Points
 * The two-dose vaccine was about 51% effective against infection from the
   omicron variant in children under 2 years old and about 37% effective among
   2- to 5-year-old kids, according to Moderna.
 * Dr. Paul Burton, Moderna’s chief medical officer, said the vaccines induced
   high levels of antibodies in the kids, which should correlate to a high level
   of protection against severe illness.
 * The FDA has promised to move quickly to authorize shots for infants, toddlers
   and preschoolers once the vaccine makers submit complete applications.

In this article

 * MRNA+3.32 (+2.33%)
   

With her husband Stephen by her side Erin Shih hugs her children Avery 6, and
Aidan, 11, after they got their second Moderna COVID-19 vaccines at Kaiser
Permanente Los Angeles Medical Center on Friday, June 25, 2021.
Sarah Reingewirtz | MediaNews Group | Getty Images

Moderna on Thursday asked the Food and Drug Administration to authorize its
Covid vaccine for children ages 6 months to 5 years old.

The vaccine was about 51% effective against infection from the omicron variant
in children under 2 years old and about 37% effective among 2- to 5-year-old
kids, according to a company press release. Dr. Paul Burton, Moderna’s chief
medical officer, said those levels are similar to two-dose protection for
adults.



The protection Moderna’s vaccine provides against infection has declined
substantially from the high-water mark of 90% effectiveness when the shots first
rolled out. The omicron variant, which has more than 30 mutations, is adept at
evading the antibodies that block the virus from invading human cells.

However, Burton said children under 6 years old who receive two doses should
have high levels of protection against severe illness. Adults have about 1,000
units of antibody after two shots with at least 70% protection against severe
disease, while children in the study had 1,400 to 1,800 units of antibody after
two doses, he said.

“What we know is that those levels of antibody will translate into very high
protection against severe disease and hospitalization,” Burton said. None of the
children in the study were hospitalized with Covid, he added.

Moderna plans to study a booster dose for children under age 6 with a redesigned
shot that targets omicron as well as the original strain of the virus that
emerged in Wuhan, China. One of the reasons vaccine effectiveness against
infection has declined so steeply is because the current shots are still
targeting the Wuhan strain, even though the virus has evolved dramatically since
it was first discovered in late 2019.

If authorized by the FDA, children under age 6 would receive two 25-microgram
shots, a much smaller dose than the 100 microgram shots currently approved by
the FDA as a primary vaccination series for adults. Burton said the safety
profile for kids is reassuring, with 0.2% of the children developing fevers of
103 degrees Fahrenheit, or 40 degrees Celsius. About 17% of kids under 2 years
old developed a fever of 100 degrees Fahrenheit while slightly more than 14% of
kids from 2 to 6 years old developed such a fever, according to a press release
Moderna issued in March on its study results.



Kids under 6 years old are in the only age group in the U.S. that is not yet
eligible for vaccination. The FDA has promised to move quickly to authorize
shots for infants, toddlers and preschoolers once the vaccine makers submit
complete applications.

Dr. Peter Marks, who heads the FDA office responsible for vaccines, told the
Senate health committee this week that the drug regulator’s committee of
independent advisors will meet to fully review the data.

“We will proceed with all due speed once we have complete applications,” Marks
said. He told the committee that the FDA will publish a timeline in the next
week for advisory committee meetings on several emergency-use applications. The
FDA is in the process of clearing several potential dates for the committee to
meet in June, according to a person familiar with matter.

Parents have been waiting for months for a way to protect their children against
the virus. During the winter omicron wave, children younger than 5-years-old
were hospitalized with Covid at five times the rate of the pandemic’s peak, when
delta was dominant, according to the Centers for Disease Control and Prevention.
About 75% of children under 11 years old had been infected with Covid as of
February, according to data released by the CDC this week.

The FDA had originally sought to fast track authorization of Pfizer’s Covid
vaccine for children under age 5 in February by clearing the first two doses of
the three-shot vaccine. However, Pfizer decided to postpone its application and
wait for data on the third shot, because the results from the first two doses
weren’t good enough.

Pfizer CEO Albert Bourla, in a podcast interview, said the first two shots only
had 30% to 40% efficacy, but he expects the third dose to significantly improve
protection. The vaccine has a three-microgram dosing level, much smaller than
the 30-micrograms used for adults.

Bourla said he hopes Pfizer’s vaccine will receive FDA authorization in June.


CNBC HEALTH & SCIENCE

Read CNBC’s latest global coverage of the Covid pandemic:

 * Philadelphia keeps indoor mask mandate in place despite Florida judge ruling
   against CDC
 * Moderna says redesigned Covid vaccine produced stronger immunity against
   omicron than current shots
 * J&J lowers 2022 revenue and earnings expectations, stops giving Covid vaccine
   sales guidance
 * William Husel, Ohio doctor accused in 14 high-dose fentanyl deaths, acquitted
   of murder
 * Where you still legally need to wear Covid face masks — and where you don’t
   anymore


TV
Squawk on the StreetWATCH LIVEWATCH IN THE APP
UP NEXT | TechCheck 11:00 am ETListen
TV
Squawk on the StreetWATCH LIVEWATCH IN THE APP
UP NEXT | TechCheck 11:00 am ETListen

Trending Now

 1. Could there be war between Russia and the West? Strategists predict what
    could happen next
    
 2. Denmark becomes the first country to halt its Covid vaccination program
    
 3. Powerball’s $473.1 million jackpot has a winner. Here’s the tax bill
    
 4. Even in a tight job market, recruiters say these 4 red flags will cost you
    the offer
    
 5. The Fed’s favorite inflation gauge rose 5.2% in March as worker pay fell
    further behind
    




 * Subscribe to CNBC PRO
 * Licensing & Reprints
 * CNBC Councils
 * Supply Chain Values
 * CNBC on Peacock
 * Advertise With Us
 * Join the CNBC Panel
 * Digital Products
 * News Releases
 * Closed Captioning
 * Corrections
 * About CNBC
 * Internships
 * Site Map
 * Manage Cookie Preferences
 * Careers
 * Help
 * Contact

 * 
 * 
 * 
 * 
 * 
 * 
 * 

NEWS TIPS

Got a confidential news tip? We want to hear from you.

Get In Touch

CNBC NEWSLETTERS

Sign up for free newsletters and get more CNBC delivered to your inbox

Sign Up Now

Get this delivered to your inbox, and more info about our products and
services. 

Privacy Policy|Do Not Sell My Personal Information|CA Notice|Terms of Service

© 2022 CNBC LLC. All Rights Reserved. A Division of NBCUniversal

Data is a real-time snapshot *Data is delayed at least 15 minutes. Global
Business and Financial News, Stock Quotes, and Market Data and Analysis.

Market Data Terms of Use and Disclaimers

Data also provided by






COOKIE SETTINGS

We and our partners collect information from your device, such as device
identifiers, IP address, and your browser type to personalize and deliver
content, marketing and advertising—across devices and platforms; for analytics
and measurement, so we can improve our services and develop new ones; to match
and combine offline data with your online activity; and for social features. We
share this information with selected partners with your consent. By clicking
“Allow All”, you consent to our use of these Cookies. Click on the Cookie
categories or the “Detailed purpose descriptions” below to learn more about
these Cookies. We will also use other Cookies that are essential for our site
and Services, including for security and fraud prevention. To learn more about
some of our partners, see the List of IAB Vendors below. Visit our Cookie Notice
and Privacy Policy to learn more.
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active

These Cookies are required for Service functionality, including security and
fraud prevention, and to enable any purchasing capabilities. You can set your
browser to block these Cookies, but some parts of the site may not function
properly.

Non-IAB Cookies‎

ENSURE SECURITY, PREVENT FRAUD, AND DEBUG

Always Active

Your data can be used to monitor for and prevent fraudulent activity, and ensure
systems and processes work properly and securely.

List of IAB Vendors‎ | Detailed Purpose Descriptions Opens in a new Tab

TECHNICALLY DELIVER ADS OR CONTENT

Always Active

Your device can receive and send information that allows you to see and interact
with ads and content.

List of IAB Vendors‎ | Detailed Purpose Descriptions Opens in a new Tab

STORE AND/OR ACCESS INFORMATION ON A DEVICE

Store and/or access information on a device

Cookies, device identifiers, or other information can be stored or accessed on
your device for the purposes presented to you.

List of IAB Vendors‎ | Detailed Purpose Descriptions Opens in a new Tab
Non-IAB Cookies‎

PERSONALISED ADS, AND AD MEASUREMENT

Personalised ads, and ad measurement

 * SELECT PERSONALISED ADS
   
   Switch Label
   
   Personalised ads can be shown to you based on a profile about you.

 * MEASURE AD PERFORMANCE
   
   Switch Label
   
   The performance and effectiveness of ads that you see or interact with can be
   measured.

 * CREATE A PERSONALISED ADS PROFILE
   
   Switch Label
   
   A profile can be built about you and your interests to show you personalised
   ads that are relevant to you.

 * SELECT BASIC ADS
   
   Switch Label
   
   Ads can be shown to you based on the content you’re viewing, the app you’re
   using, your approximate location, or your device type.

 * TARGETED ADVERTISING COOKIES
   
   Switch Label
   
   These Cookies are used to collect data about your browsing habits, use of the
   Services, your preferences, and your interaction with advertisements across
   platforms and devices for the purpose of delivering targeted advertising
   content, both on our Services and on third party sites. Third-party sites and
   services also use Targeting Cookies to deliver content, including
   advertisements relevant to your interests on the Services. If you reject
   these Cookies, you will see less relevant advertising.

List of IAB Vendors‎ | Detailed Purpose Descriptions Opens in a new Tab
Non-IAB Cookies‎

PERSONALISED CONTENT, CONTENT MEASUREMENT, AUDIENCE INSIGHTS, AND PRODUCT
DEVELOPMENT

Personalised content, content measurement, audience insights, and product
development

 * DEVELOP AND IMPROVE PRODUCTS
   
   Switch Label
   
   Your data can be used to improve existing systems and software, and to
   develop new products

 * SELECT PERSONALISED CONTENT
   
   Switch Label
   
   Personalised content can be shown to you based on a profile about you.

 * APPLY MARKET RESEARCH TO GENERATE AUDIENCE INSIGHTS
   
   Switch Label
   
   Market research can be used to learn more about the audiences who visit
   sites/apps and view ads.

 * CREATE A PERSONALISED CONTENT PROFILE
   
   Switch Label
   
   A profile can be built about you and your interests to show you personalised
   content that is relevant to you.

 * MEASURE CONTENT PERFORMANCE
   
   Switch Label
   
   The performance and effectiveness of content that you see or interact with
   can be measured.

 * CONTENT SELECTION COOKIES
   
   Switch Label
   
   This group is so Content Selection IAB group can have an id

List of IAB Vendors‎ | Detailed Purpose Descriptions Opens in a new Tab
Non-IAB Cookies‎

SOCIAL MEDIA COOKIES

Social Media Cookies

These Cookies are set by social media platforms on the Services to enable you to
share content with your friends and networks. Social media platforms have the
ability to track your online activity outside of the Services. This may impact
the content and messages you see on other websites you visit.

Non-IAB Cookies‎


BACK BUTTON PERFORMANCE COOKIES



Vendor Search Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label


 * 33ACROSS
   
   HOST DESCRIPTION
   
   VIEW COOKIES
   
   
    * Name
      cookie name

Confirm My Choices


We and our partners collect information from your device, such as device
identifiers, IP address, and your browser type to personalize and deliver
content, marketing and advertising—across devices and platforms; for analytics
and measurement, so we can improve our services and develop new ones; to match
and combine offline data with your online activity; and for social features. We
share this information with selected partners with your consent. By clicking “I
accept”, you consent to our use of these Cookies. Click Manage Choices to learn
more about these. We will also use other Cookies that are essential for our site
and Services, including for security and fraud prevention. To learn more about
some of our partners select Show Vendors. You can adjust your preferences at any
time via the “Manage Cookie Preferences” link in the footer of relevant
NBCUniversal websites or in-app settings. Visit our Cookie Notice and Privacy
Policy to learn more.


WE AND OUR PARTNERS PROCESS DATA FOR THE FOLLOWING PURPOSES:

Store and/or access information on a device. Personalised ads, and ad
measurement. Personalised content, content measurement, audience insights, and
product development. List of IAB Vendors

I Accept Manage Choices